AptarGroup (ATR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 May, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who announced his planned retirement after nearly 10 years in the role.
The meeting was held virtually to increase accessibility for all stockholders.
The agenda and meeting rules were made available online, and the meeting was conducted per bylaws.
Board and executive committee updates
Gael Touya, with over 30 years at the company, will become President and CEO on September 1, 2026, with the current CEO remaining as advisor through year-end.
The board expects to appoint Gael Touya as a director on September 1, 2026.
Key executives and independent accountants were introduced and present for the meeting.
Overview of voting outcomes
A quorum was confirmed, and polls were open for voting on all agenda items.
Four directors were elected to serve until the 2029 annual meeting.
Advisory approval of executive compensation and ratification of the independent accounting firm for 2026 both passed by majority vote.
Latest events from AptarGroup
- Pharma innovation, operational recovery, and sustainability drive strong 2025 performance.ATR
16th Annual Wells Fargo Industrials & Materials Conference9 Jun 2026 - Pharma-led growth, innovation in drug delivery, and strong financials drive long-term value.ATR
Jefferies Global Healthcare Conference 20269 Jun 2026 - Sales up 11% but margin pressure and pharma destocking weighed on profit; Q2 growth expected.ATR
Q1 20265 May 2026 - Q4 2025 sales up 14% but net income down 26%; $600M share buyback authorized.ATR
Q4 202517 Apr 2026 - Pharma innovation, digital health, and sustainability drive robust growth and future outlook.ATR
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - Proxy covers director elections, pay, auditor ratification, and strong ESG and governance focus.ATR
Proxy filing27 Mar 2026 - Annual meeting covers director elections, say-on-pay, and auditor ratification.ATR
Proxy filing27 Mar 2026 - Pharma-led innovation, sustainability, and disciplined capital drive robust 2025 results and outlook.ATR
47th Annual Raymond James Institutional Investor Conference6 Mar 2026 - 2025 growth led by pharma and innovation, with margin expansion and global operational strength.ATR
Bank of America 2026 Global Agriculture and Materials Conference2 Mar 2026